AbbVie maintains its leadership position through a diversified therapeutic portfolio spanning immunology, neuroscience and oncology. Following Humira’s loss of exclusivity in 2023, the company has rapidly rebuilt growth engines with Skyrizi and Rinvoq, which collectively generated over $22 billion in global sales last year. In neuroscience, Botox and Vraylar contributed 17% of total revenues, growing double digits year-over-year. The company’s robust R&D allocation—approximately $8 billion annually—supports a late-stage pipeline that includes next-generation immunology treatments and a Phase 3 trial for an SBS-IF therapy expected to launch in mid-2026.

In the third quarter, AbbVie reported revenue of $15.78 billion, up 9.1% year-over-year, and adjusted EPS of $1.86, beating consensus by $0.09. Net margin held at 4.0%, reflecting disciplined cost management despite increased rebate expenses. The company reaffirmed full-year earnings guidance of $3.32–$3.36 per share and anticipates revenue growth in the high single digits for 2026, driven by accelerating immunology and neuroscience sales as well as new product launches in oncology.

AbbVie celebrated its 54th consecutive annual dividend increase, raising the quarterly payout by 5.5% to $1.73 per share. This marks a 3.0% yield on year-end market capitalization of approximately $404 billion. The payout ratio stands at 497%, underpinned by free cash flow of $15 billion over the past twelve months. Generali Asset Management reduced its holding by 7.3% last quarter, while several large institutions—including Norges Bank and Vanguard—either initiated or expanded positions, reflecting broad confidence in AbbVie’s capacity to sustain dividend growth and invest in future innovation.